World Vaccine Congress Europe 2026 Exhibitors
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
132 organizations exhibit at World Vaccine Congress Europe 2026 — 97 suppliers and service providers, 27 vaccine and drug developers, 4 public-health and non-profit bodies and 4 academic bodies. 78 of them also present on the scientific program, with 93 presentations between them. Most represented: African Field Epidemiology Network (AFENET) (5 on the program), Tonix Pharmaceuticals (3 on the program), UK Health Security Agency (UKHSA) (2 on the program). 132 of them have their own page in this guide. As of Sep 26, 2026.
All 251 organizations at World Vaccine Congress Europe 2026 →
Topic
Top represented
Showing 1–30 of 132 organizations
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
African Field Epidemiology Network (AFENET) Kampala, Uganda | |
Non-profit network that trains field epidemiologists and supports disease surveillance, outbreak response and immunization programs across Africa. | Booth Exhibiting (no floor booth listed) Talk Mon Oct 19 15:45 Talk Tue Oct 20 11:30 |
Tonix Pharmaceuticals Chatham, NJ | |
Biopharmaceutical company whose vaccine work includes TNX-801, a horsepox-based vaccine platform. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Vectored Vaccine Platforms: from design to improving efficacy Platforms & delivery Talk Wed Oct 21 13:15 |
UK Health Security Agency (UKHSA) London, UK | |
UK agency that plans for, prevents and responds to health threats, providing scientific and operational leadership nationally and globally. | Booth Exhibiting at Booth 417 Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Panel Tue Oct 20 17:10 One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy How tracking disease in people, animals and the environment together can set vaccine priorities for infections that jump from animals, like bird flu. One Health & ecosystems Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. |
Develops mucosal vaccines against serious infectious diseases on a proprietary platform of outer membrane vesicles (OMVs). | Booth Exhibiting (no floor booth listed) Talk Mon Oct 19 10:30 Talk Wed Oct 21 10:30 From Innovation to Impact: Translating OMV Vaccine Technology into Clinical Reality How a developer and a contract manufacturer take vaccines made from outer membrane vesicles, tiny bacterial bubbles, from research toward clinical trials. |
Japanese vaccine maker linked to Osaka University, producing influenza and other vaccines. | Booth Exhibiting at Booth 226 Talk Tue Oct 20 14:30 |
Uses its AI-Immunology platform to discover and design vaccines against bacterial and viral infections and cancer. | Booth Exhibiting at Booth 216 Talk Wed Oct 21 11:00 Talk Wed Oct 21 11:30 |
Laboratory services for drug discovery and development, including central laboratory and specialty biomarker services. | Booth Exhibiting at Booth 410 Talk Tue Oct 20 14:00 |
Develops circular RNA vaccines, including candidates against yellow fever and dengue. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 16:00 Safe and Efficacious Circular RNA Vaccines to Treat Yellow Fever and Dengue Infectious disease & AMRPlatforms & delivery |
Belgian medical device company making delivery devices, including the VAX-ID intradermal system, for prophylactic, diagnostic and therapeutic use. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 12:45 |
Global management consulting firm. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. |
The clinical research business of Thermo Fisher Scientific, supporting therapies from early development through clinical research and commercial manufacturing. | Booth Exhibiting (no floor booth listed) |
Develops silicon microneedle devices for intradermal delivery; its lead product, Bella-mu, administers volumes up to 0.5 mL. | Booth Exhibiting at Booth 540 Talk Wed Oct 21 10:30 How can a microneedle manufacturer contribute to the success of cancer vaccine developers? Cancer & therapeutic vaccinesPlatforms & delivery |
Swiss centre of expertise in adjuvants and vaccine formulation that develops adjuvants and supplies them at GMP grade under open-access terms. | Booth Exhibiting at Booth 537 Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. |
HL Hilleman Laboratories Singapore, Singapore | |
Vaccine research and development organization, founded by MSD and Wellcome, developing affordable vaccines for low- and middle-income countries. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Forging Outbreak-ready Vaccine Partnerships Infectious disease & AMRSupply, safety & access Talk Wed Oct 21 09:00 The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World How governments and industry can keep vaccines flowing fairly across borders in an emergency as countries push to make vaccines at home. Supply, safety & accessBioprocess & manufacturing Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. |
Contract research organization for infectious disease and zoonoses research, offering bioanalytical services and preclinical studies; part of GD Group. | Booth Exhibiting at Booth 413 Talk Tue Oct 20 16:15 |
Croda Pharma Snaith, United Kingdom | |
Supplies adjuvant systems, lipids for nucleic acid delivery and high-purity excipients for vaccine and drug formulation. | Booth Exhibiting at Booth 214 Talk Tue Oct 20 14:00 Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. |
Novavax Gaithersburg, MD | |
Vaccine company developing protein-based vaccines with its Matrix-M adjuvant, including a marketed COVID-19 vaccine. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 14:00 |
Supplies pharmaceutical excipients and vaccine adjuvants. | Booth Exhibiting at Booth 311 Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. Talk Wed Oct 21 10:45 |
Acuitas Therapeutics Vancouver, Canada | |
Develops lipid nanoparticle (LNP) delivery systems for mRNA vaccines and therapeutics, licensed to partner companies. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 14:15 |
Alcimed Paris, France | |
Innovation and new-business consulting firm helping life sciences clients explore and develop new markets and products. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 21 13:45 |
Specialises in quantifying HLA-presented peptides, with liquid biopsy and AI platforms supporting safer, more effective immunotherapies. | Booth Exhibiting at Booth 553 |
Drug delivery partner supplying delivery devices, formulation and development services, including nasal delivery, to pharmaceutical companies worldwide. | Booth Exhibiting (no floor booth listed) |
CDMO offering one-stop development and manufacturing of mRNA vaccines and therapeutics, with research support from group company Axcelead DDP. | Booth Exhibiting at Booth 422 Talk Tue Oct 20 16:00 |
Biological E Hyderabad, India | |
Indian vaccine and pharmaceutical manufacturer supplying vaccines to low- and middle-income countries. | Booth Exhibiting at Booth 307 Talk Mon Oct 19 10:45 |
Biomedical Primate Research Centre (BPRC) Rijswijk, Netherlands | |
Research institute running non-human primate studies of infectious and other diseases, including preclinical vaccine research. | Booth Exhibiting (no floor booth listed) |
Booth Exhibiting at Booth 425 Talk Tue Oct 20 14:15 | |
Develops supercritical CO2 processes, offering feasibility studies, scale-up, licensing and production, including continuous manufacturing of nanocarriers. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 21 11:30 Redefining Nanocarrier Manufacturing with Scalable Continuous scCO₂ Processing for Advanced Vaccine Delivery Bioprocess & manufacturingPlatforms & delivery |
Clinical trial laboratory services company providing central lab testing and specialty assays for drug and vaccine trials. | Booth Exhibiting at Booth 427 Talk Mon Oct 19 15:45 |
Develops glycoconjugate vaccines, including a K1/K2 vaccine against hypervirulent Klebsiella pneumoniae in first-in-human trials. | Booth Exhibiting (no floor booth listed) |
Group of contract testing and manufacturing companies, including Clean Cells and Naobios, serving vaccine and biologics developers. | Booth Exhibiting at Booth 220 Talk Wed Oct 21 11:30 Considerations on the development and manufacturing qualities of Human Viral Challenge Agents (HVCA) How viruses used to deliberately infect volunteers in vaccine and drug studies are made to strict quality standards to keep participants safe. |
Instantly find 20 buyers from World Vaccine Congress Europe 2026 exhibitors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World Vaccine Congress Europe 2026 by
Organization type
Topic
Exhibit hall
- Exhibitors 132
Everyone
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction